Roivant Drug Shows Success in Uveitis Phase 3 Trials
The experimental drug brepocitinib met all primary endpoints in recent clinical studies for non-infectious uveitis.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Should the government prioritize fast-tracking regulatory approval for new drug treatments for rare, debilitating diseases?
Roivant and Priovant announced positive Phase 3 results for brepocitinib, a treatment for non-infectious uveitis. The clinical program showed that the drug significantly outperformed placebos in managing inflammation and achieving steroid-free patient outcomes.
Why it matters
These results provide a potential new treatment pathway for patients suffering from non-infectious uveitis, a condition that can lead to vision loss. The findings bolster the clinical profile of brepocitinib as the companies move toward regulatory submission.
In Phase 3 trials involving 371 patients, 62% of those treated with 45 mg of daily brepocitinib achieved steroid-free quiescence compared to 20% on placebo. The dropout rate due to adverse events was 3% among participants.
The players
Roivant
This is a biopharmaceutical company that focuses on developing and commercializing innovative medicines across various therapeutic areas.
Priovant
This is a subsidiary or partner entity involved in the clinical development and regulatory pursuit of the brepocitinib treatment.
The details
The CLARITY-1 and CLARITY-2 studies demonstrated that patients on brepocitinib maintained longer periods without treatment failure, with a median time exceeding 48 weeks versus approximately 12 weeks for the placebo group. Additionally, 42% of eyes treated with the drug saw resolution of macular edema at Week 48, far surpassing the 4.8% rate observed in the placebo arm.
Timeline
October 21, 2026: Roivant hosts investor call regarding Phase 3 trial results.
December 9, 2026: Roivant hosts an investor day.
First half of 2027: Priovant plans to file a supplemental drug application.
The Big Picture
The CLARITY clinical program establishes the performance benchmarks for modern non-infectious uveitis therapies. This discovery shifts the trajectory for future treatment by demonstrating high efficacy in steroid-free patient outcomes.
This development offers a potential future treatment option for patients who currently rely on corticosteroid regimens to manage non-infectious uveitis. The clinical results suggest a path toward maintaining vision health with fewer long-term complications from steroids.
The takeaway
The successful trial results highlight the potential for non-steroidal treatments to change long-term management strategies for chronic eye inflammation. Patients should continue working with their ophthalmologists to monitor current standard-of-care options until new therapies reach the market.
What happens next
Priovant intends to file a supplemental New Drug Application for the treatment of non-infectious uveitis during the first half of 2027.
Further reading
Learn more about current pharmaceutical development in the Biotech sector.
Live Poll
Should the government prioritize fast-tracking regulatory approval for new drug treatments for rare, debilitating diseases?
